Unlike some countries that have flattened the curve, the US is experiencing a sharp rise in COVID-19 cases. In this video — part of a series on the scientific and investment implications of COVID-19 —Biotech Analyst, Agustin Mohedas, explains why the US trajectory has diverged, noting how the outbreak’s dynamics are changing and what that could mean for the next phase of the pandemic.

Key takeaways:

  • COVID-19 case numbers are rising in the US, even as many other countries have successfully flattened the curve. One reason may be a lack of coordinated response to the disease in the US and the decision to reopen economies despite comparatively high active case counts.
  • That said, hospitalisation rates have declined as the average age of the newly infected skews younger. In addition, doctors and nurses now have better knowledge of how to treat the disease, helping survival rates.
  • Large infection numbers could also make it easier for drug makers to find enough patients for testing potential vaccines, some of which are moving into late-stage clinical trials.